DOCSLIB.ORG

PHOENIX ALL-IN-ONE Magazine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PHOENIX ALL-IN-ONE Magazine 04/2018 ALL-IN-ONE MAGAZINE AWARDS 22nd PHOENIX Pharmaceutical Science Awards in Frankfurt FULL-SERVICE Order-to-Cash-Cycle from HEALTH LOGISTICS Germany PIÙ FORTE INSIEME Annual congress of Italian phar- macy cooperation Valore Salute AiO Magazine 2018_4.indd 1 16.11.2018 16:48:48 2 Editorial € € BUSINESS LOWER OPTIMISED GROWTH COSTS PROCESSES SIMPLICITY Dear reader, We know that you are confronted with a lot of challenges in today’s European healthcare markets. And we know that just showing EUROPE you where we see room for improvement through our BI services only takes you half 3 PHOENIX Pharmaceutical Science Awards 2018 the way. That is why we offer solutions that 4 Order-to-cash-cycle at Health Logistics analyse the markets and execute our 5 FMD workshop at International Symposium in value-adding services under the PHOENIX Serbia All-in-One brand across 27 countries in Europe to solve the challenges you face. 14 As the leading fully integrated European COUNTRIES Healthcare Provider with Wholesale, Pre-wholesale, 2,500 own and more than 6 Netherlands: Specialised care at the patient’s home 13,400 cooperation pharmacies in Europe 7 Austria: Pharmacy Member Days, “Tag des Wissens” we provide experienced experts in all our & Pharma Marketing Club Austria markets that help you to grow. 8 Switzerland: Healthcare Logistics partnership between Accord Healthcare and Amedis Talk to us and we will prove to you that we 9 Italy: Valore Salute Convention can make a difference you need. We look 10 Hungary: New Partnership with Zentiva forward to a close and successful coopera- 11 UK: Longtime partnership with Accord Healthcare tion with you! Kind regards Stefan Jung ALL-IN-ONE NEWSFLASH Commercial Head of Corporate Pharma Services & Sourcing 12 Serbian Congress of Pharmacy // PHOENIX group Superbrands Awards for BENU Slovakia IMPRINT The All-in-One Magazine is published by Editorial Team: Title Page: PHOENIX Pharmahandel GmbH & Co KG, Olaf Christiansen (Chief Editor, +49 621 8505- PHOENIX Pharmaceutical Science Award Corporate Pharma Services & Sourcing, 8444, [email protected]), Reto Ceremony with industry partners Pfingstweidstraße 10-12, 68199 Mannheim, Brändli, Carolin Dörner, Walter Fortunat, Julia in Frankfurt on 25th October 2018. Germany. Haßfeld, Clemens Homburg, Arthie Krishnas- Photo: Marc Fippel. All rights reserved, no part of this publication ing, David Lea, Danijela Simovic, Thomas Printed by: may be reproduced without prior permission Sommereder. Konica Minolta Marketing Service, by the publisher. Köln AiO Magazine 2018_4.indd 2 16.11.2018 16:48:49 PHOENIX All-in-One | Science Awards 3 PHOENIX SUPPORTS SCIENTIFIC RESEARCH For the 22nd time, PHOENIX group has awarded the ter, Goethe University Frankfurt am Main, evaluated best scientific research projects with the PHOENIX the papers from the branches pharmacology and clini- Pharmaceutical Science Awards. Industry representa- cal pharmacy, pharmaceutical biology, pharmaceutical tives from Accord, CSL Behring, Mylan and Teva chemistry and pharmaceutical technology. joined the award ceremony in Frankfurt, Germany. A gala event framed the festive award ceremony. The event also marked the start of the 25th anniversa- Can depression be treated with Magic Mushrooms? ry of the PHOENIX group. In his opening speech, Oliver Can a bacterium produce wound dressings? These are Windholz, CEO PHOENIX group (picture on top), only two of the questions that the winners of this referred to the almost equally long-standing acknowl- year’s PHOENIX Pharmacy Science Award are dealing edgement of pharmaceutical excellence through the with. On 25th October 2018, the prize, endowed with PHOENIX Pharmacy Science Award: “With more than 40,000 Euros, was awarded in Frankfurt’s Palmengar- 80 award-winning research projects from Germany, ten. The prize is awarded annually for innovative and Austria and Switzerland, the PHOENIX Pharmaceutical outstanding research projects in the pharmaceutical Science Award is our contribution to ensuring that top sector. Participants from Germany, Switzerland and pharmaceutical research has a home in the DACH Austria submitted their contributions in four catego- region. Top-class research that can be groundbreaking ries. An independent jury led by Professor Jörg Kreu- for the healthcare worldwide”. PHOENIX Pharmaceutics Science Award 2018 - Molecular biological analyses of „Magic Mushrooms“ - Bacterial nanocellulose for the production of wound dressings - New therapeutic approaches for the treatment of non-alcoholic fatty liver hepatitis - The role of receptor Plexin-B2 and it’s ligand Semaphorin-4C in inflammatory pain AiO Magazine 2018_4.indd 3 16.11.2018 16:48:51 4 PHOENIX All-in-One | Germany ORDER-TO-CASH-CYCLE AT HEALTH LOGISTICS The Service Center of Health Logistics is an important part of the order-to-cash-cycle in supporting clients with their requests. Health Logistics, a German PHOENIX company, is a solution will be discussed and developed in a one- or full service logistic provider specialised in the fields two-day workshop to offer the best possible solution. of pharmaceuticals, healthcare and biotechnology. The Health Logistics Service Centre is located in For 17 years, the company has been successful with Bruchsal, Germany. The multilingual Service Centre a proven concept in Germany which includes Agents are currently able to supervise customer value-adding services for industry partners. orders in German and English. Based on their high Consequently, the client can easily outsource the flexibility and professional qualification, a competent entire order-to-cash-cycle. In cooperation with contact person is always available. PHOENIX group, Health Logistics is able to provide a If needed, the customer services are expandable in the Europe-wide network and implement Pan-European future to match the need of our industry partners. distribution solutions. The services include: • GDP compliant customer qualification • Customer order acceptance and documentation • Invoicing / accounting in the name of the client • Observation of incoming payments / credit limits / reminder • Reporting • Logistical order handling This service is ideal for start-up companies that want More information: to bring new products successfully to the market but Clemens Homburg, Managing do not have a logistic infrastructure yet and are limited Director Health Logistics GmbH in setting up own management processes. In consul- +49 7251 93 25 7-0 tation with the client, an individual tailor-made [email protected] AiO Magazine 2018_4.indd 4 16.11.2018 16:48:54 PHOENIX All-in-One | Serbia 5 INTERNATIONAL SYMPOSIUM IN SERBIA With wholesale, healthcare logistics and retail, @PHOENIX: The Journey” in which he presented PHOENIX group is facing challenges concerning FMD the path of implementation of the EU FDA regula- – therefore, well in advance of the deadline in Febru- tion within the PHOENIX group. The deadline for ary 2019, we began to work with our industry partners the implementation of the EU FMD is 9th February to get prepared. Dr. Tikesh Ramtohul, Head of Serili- 2019. At the workshop, Serbian producers shared their zation at PHOENIX group, joined the 14th Internation- experience regarding their international cooperation al Symposium of the Medicines and Medical Devices with EU partners. Representatives from GSK and the Agency (SERBIA) in Kragujevac, the fourth biggest Croatian Organisation for the Verification of Medicines Serbian city, located 140 kilometres southeast of the Authenticity joined Tikesh on stage. capital Belgrade. The heading of the symposium was “From vision to practice in the regulation of medi- cines and medical devices for human and veterinary use”. Every year, the Symposium is organised by the Agency for Medicines and Medical Devices of Serbia (ALIMS), in cooperation with the Serbian Chamber of Com- merce, the Association of Innovative Medicines Manu- facturers – INOVIA and the Association of Foreign Ge- neric Drug Producers – GENEZIS. The Symposium is primarily intended for medicines manufacturers and market authorisation holders, producers of medical devices, as well as healthcare professionals, repre- sentatives of regulatory bodies and universities. FMD at PHOENIX group As a trusted and quality-oriented healthcare pro- The sessions including the following topics – harmo- vider in 27 European countries, PHOENIX group nisation with EU requirements, quality of Medicines for takes the topic of Falsified Medicines Directive Veterinary use, international cooperation of National (FMD) very seriously. At PHOENIX, several busi- Regulatory Authorities, new legislation in the field of ness segments are impacted: retail, wholesale, medical devices, Clinical trials of medicines for human healthcare logistics (pre-wholesale) and GMP use and serialisation/FMD, which was the main point services, such as repackaging. PHOENIX will be of interest for PHOENIX Serbia. Dr. Tikesh Ramtohul ready and FMD-compliant by 9th February 2019. (picture below) gave a presentation on the topic “FMD In addition to the technological aspects of the FMD implementation, the PHOENIX countries are investing a lot of effort locally in offering appropri- ate education and training to their employees, in order to make the transition into the FMD era as seamless as possible, which by extension, implies better service to our end customers, in line with our patient-centric approach. Read more about FMD on our website: AiO Magazine 2018_4.indd 5 16.11.2018 16:48:56 6 PHOENIX
Load more

Recommended publications
  • Annual Report 2019/20 Contents
    ANNUAL REPORT 2019/20 CONTENTS 02 GROUP 20 EXTRACT FROM THE MANAGEMENT REPORT CONSOLIDATED FINANCIAL STATEMENTS 03 Fundamental information about the group 07 Economic report 21 Consolidated income statement 17 Risk and opportunity report 22 Consolidated statement of comprehensive income 19 Forecast 23 Consolidated statement of financial position 25 Consolidated statement of cash flows 27 Consolidated statement of changes in equity Annual Report _ 2019 / 2020 GROUP MANAGEMENT REPORT 2019/20 2 03 FUNDAMENTAL INFORMATION ABOUT THE GROUP 03 PHOENIX 05 Strategy and group management 06 Processes and organisation 07 ECONOMIC REPORT 07 Economic environment 07 Business development at a glance 09 Financial performance 13 Assets and liabilities 14 Financial position 15 Employees 17 RISK AND OPPORTUNITY REPORT 17 Risk management 17 Risks 18 Opportunities 18 Management Board’s overall assessment of the risks and opportunities 19 FORECAST 19 Future economic environment 19 Future development of PHOENIX 19 Management Board’s assessment of the group’s future position PHOENIX Pharmahandel GmbH & Co KG Annual Report _ 2019 / 2020 Group management report Fundamental information about the Group FUNDAMENTAL INFORMATION ABOUT THE GROUP ° Leading market position in European pharmaceutical wholesale ° Corporate strategy builds upon three pillars ° Digitalisation brings direct communication with end customers ° Projects and initiatives aim to achieve process optimisation and cost efficiency PHOENIX NET TURNOVER PER REGION in % Leading European healthcare provider PHOENIX, with its headquarters in Mannheim, Germany, is FY 2018 / 19 a leading European healthcare provider and is one of the largest family businesses in both Germany and Europe. Its core Eastern Europe 16.3 34.5 Germany business is pharmaceutical wholesale and pharmacy retail.
    [Show full text]
  • The 2013 USC Marshall International Case Competition. Each Year We
    Welcome to the 2013 USC Marshall International Case Competition. Each year we invite students from schools around the world to participate in this competitive event. Of the thirty teams attending this year, 19 teams represent schools from outside the United States. We embrace all of you and hope you enjoy your brief visit to Los Angeles and the University of Southern California. This year’s case presents issues which are current and very real to this business and their competitors in this and related industries. Thus, do not feel that the only relevant and available information is found within the four corners of this document. While some of the information provided here was only made available on the day we went to press, this industry is changing so quickly that there is no doubt in our minds that additional relevant information will appear in the days running up the time you receive this document. Thus, you should feel free to look for, and use, additional information which you may find online in completing your analysis of this case. References to some additional sources of information may be found in the Appendix. In addition to testing your skills in strategic analysis this year’s case seeks to address a topic which is very relevant to each of you as consumers. Your own experience with this industry and with the companies covered in the case will no doubt influence your perspective. Give voice to your own insights. We are certain that the panel of judges and company representatives are willing and eager to listen to your recommendations for today and the future.
    [Show full text]
  • Global CEO Appointments: About the High Pay Centre Contents a Very Domestic Issue
    THE NEW CLOSED SHOP: GLOBALWHO’S DECIDING CEO APPOINTMENTS:ON PAY? THE MAKE UP OF REMUNERATION COMMITTEES A VERY DOMESTIC ISSUE High Pay Centre Global CEO appointments: About the High Pay Centre Contents A very domestic issue The High Pay Centre is an The High Pay Centre is resolutely independent non-party think tank independent and strictly non- 4 Foreword established to monitor pay at the partisan. It is increasingly clear that top of the income distribution and there has been a policy and market 5 Executive Summary set out a road map towards better failure in relation to pay at the top business and economic success. of companies and the structures 6 Introduction of business over a period of years We aim to produce high quality under all governments. It is now 7 North America: Staying home research and develop a greater essential to persuade all parties that understanding of top rewards, there is a better way. 9 Western Europe: Trickling across the pond company accountability and business performance. We will The High Pay Centre is grateful to its 12 China: From state to state communicate evidence for change supporters for funding this work. to policymakers, companies and 13 Japan: Decades on a ladder other interested parties to build a @highpaycentre consensus for business renewal. www.highpaycentre.org 14 Rest of Asia: More introspection 15 Eastern Europe: Putin’s boys This report was prepared for 15 Latin America: Impregnable borders the High Pay Centre by David Bolchover. David Bolchover is 16 Conclusion the author of Pay Check: Are Top Earners Really Worth It? and he sits 18 Appendix: Methodology and companies in the study on the advisory board of the High Pay Centre.
    [Show full text]
  • Executive Board of the PHOENIX Group 08 Report of the Supervisory Board 10 Members of the Supervisory Board 11 PHOENIX Group in the Capital Market
    HEALTHCARE THAT FITS INTO YOUR LIFE ANNUAL REPORT 2019 / 2020 WE DELIVER HEALTH. The PHOENIX group is a leading healthcare In pharmaceutical wholesale, the PHOENIX provider in Europe, reliably supplying people group has 161 distribution centres in 27 Euro- EACH AND EVERY DAY. with drugs and health products every day. pean countries from which it supplies drugs ACROSS EUROPE. The PHOENIX group originated from the and other health products to pharmacies and merger of five regional pharmaceutical medical institutions. Numerous other pro- wholesale businesses in Germany in 1994. ducts and services for pharmacy customers Today, with more than 39,000 employees, complete the port folio – from assistance in the company offers unique geographical advising patients to modern goods manage- coverage throughout Europe, making a vital ment systems to pharmacy cooperation contribution to comprehensive healthcare. programmes. With more than 13,500 inde- The PHOENIX group’s vision is to be the best pendent pharmacies in the company’s integrated healthcare provider – wherever cooperation and partner programmes, the it is active. This means providing each cus- PHOENIX group’s pharmacy network is the tomer group with the best possible products largest of its kind in Europe. The PHOENIX and services along the entire pharmaceutical Pharmacy Partnership acts as the Europe- supply chain. wide umbrella for the PHOENIX group’s 13 pharmacy cooperation programmes in 16 countries. In pharmacy retail, the PHOENIX group ope- Pharma Services provides services along rates more than 2,700 of its own pharmacies the entire pharmaceutical supply chain. in 15 countries – of which over 1,500 operate The “All-in-One” concept stands for a com- under the corporate brand BENU.
    [Show full text]
  • The World's 200 Richest People
    The World’s 200 Richest People (2005) Compiled by Forbes (Each listing will include the rank, name, age, worth [in $billions], country of citizenship, and residence, along with brief biographical information.) 1 William Gates III, 49, $46.5bn, USA, Medina, Wash. (USA) Industry: Software Marital Status: married , 3 children Harvard University, Drop Out Gates was given honorary knighthood in March, but don’t call him Sir William: the title is only good for citizens of the Commonwealth. He is staying plenty busy pressing Microsoft beyond PCs into television set-top boxes, games, cell phones. “Software is where the action is,” Gates proclaimed to company researchers last August. Competition from rival open source operating system, Linux, is stalling Microsoft’s growth in the server market, but desktop dominance remains intact: Windows installed in 94% of PCs being sold. Next version, Longhorn, should be ready in 2006. Microsoft, meanwhile, is pursuing online music, photos and search software. Gates is methodically diversifying his wealth: He sells 20 million shares each quarter, reinvests through Cascade Investment in non-tech companies, including big stakes in Cox Communications, Canadian National Railway, Republic Services. World’s biggest philanthropist also devoting $27 billion to good deeds. Bill & Melinda Gates Foundation fights infectious diseases (hepatitis B, AIDS), funds vaccine development, helps high schools. 2 Warren Buffett, 74, $44.0bn, USA, Omaha, Neb. (USA) Industry: Investments Marital Status: widowed , 3 children University of Nebraska Lincoln, Bachelor of Arts / Science Columbia University, Master of Science Newspaper delivery boy filed first 1040 at age 13; claimed $35 deduction for bicycle. Studied under Benjamin Graham at Columbia.
    [Show full text]
  • Annual Report 2013/14 Pdf (4
    Annual Report 2013/14 PHOENIX Pharmahandel GmbH & Co KG Pfi ngstweidstrasse 10-12 68199 Mannheim Germany group www.PHOENIXgroup.eu PHOENIX Annual Report 2013/14 WE GO FORWARD Annual Report 2013/14 PHOENIX group PHOENIX group in figures Key figures of the PHOENIX group 2009/10 2010/11 2011/12 2012/13 2013/14 Revenue in EUR k 21,317,594 21,737,772 21,660,649 21,218,687 21,792,370 Total operating performance 1) in EUR k 24,433,939 25,062,613 25,479,749 25,251,336 25,917,392 Total income 2) in EUR k 2,009,062 2,078,580 2,249,687 2,319,147 2,217,593 Profit before tax 3) in EUR k 242,532 270,060 294,775 230,723 143,097 Adjusted profit before tax 4) in EUR k 306,518 324,038 294,775 329,156 253,099 Equity in EUR k 1,092,612 5) 1,772,409 5) 1,935,623 2,103,800 2,161,841 Equity ratio in % 13.5 23.4 26.1 28.7 29.4 Net debt in EUR k 3,678,418 2,176,588 1,855,743 1,611,518 1,331,627 Company rating (Standard & Poor’s) B+ BB− BB BB Employees (total) 28,156 27,873 6) 29,038 6) 28,698 28,555 Employees (full-time) 23,261 23,206 23,850 23,932 23,850 1) Total operating performance = revenue + handled volume (handling for service charge). 2) Total income = gross profit + other operating income (previous years adjusted due to changes in reporting).
    [Show full text]
  • PHOENIX PIB Dutch Finance B.V
    PHOENIX PIB Dutch Finance B.V. Annual Report for the year 2018/19 PHOENIX PIB Dutch Finance B.V. Contents Directors’ report 1 Financial statement 2018/19 6 Balance sheet as at 31 January 2019 7 Statement of income for the year 2018/19 8 Cash flow statement for the year 2018/19 9 Notes to the 2018/19 financial statements 10 Other information 27 i PHOENIX PIB Dutch Finance B.V. Directors’ report The Board of Directors of PHOENIX PIB Dutch Finance B.V. (the “Company”) is pleased to present you its financial statements for the financial year ended 31 January 2019. All amounts in the directors’ report are stated in EUR 1,000, unless indicated otherwise. General information on the legal entity PHOENIX PIB Dutch Finance B.V., with its statutory seat and its office in Maarssen, the Netherlands, serves as a financing company for the affiliated company PHOENIX PIB Finance B.V. and was founded on 17 April 2013. PHOENIX PIB Dutch Finance B.V. is a fully-owned subsidiary of PHOENIX PIB Dutch Holding B.V., Maarssen, the Netherlands and is ultimately owned by PHOENIX Pharma SE, Mannheim, Germany (“PHOENIX”). The Company is part of a fiscal unity for corporate income tax purposes together with the principal of the fiscal unity, PHOENIX PIB Dutch Holding B.V. and PHOENIX PIB Finance B.V., a fully-owned subsidiary of PHOENIX PIB Dutch Holding B.V. The Company recognizes its current tax result in the financial statements. The company has signed an advanced pricing agreement with the Dutch tax authorities.
    [Show full text]
  • Corporate Rating Component Scores Europe, the Middle East, and Africa Q4 2020
    Corporate Rating Component Scores Europe, the Middle East, and Africa Q4 2020 FALSE EMEA Corporate Rating Component Scores Oct. 31, 2020 Corporate Rating Component Scores Europe, the Middle East, and Africa S&P Global Ratings is publishing the rating component scores report for its public issuer credit ratings in Europe, the Middle East, and Africa (EMEA). This article reflects the scores defined in of our corporate methodology, accompanied by charts that show the distribution of aggregated scores. We believe that the list and charts enhance benchmarking across industries and rating levels for all market participants. We disclose these scores in line with the information we provide in our rating research publications, such as research updates and full analyses. By releasing all scores for public corporate ratings in EMEA, S&P Global Ratings confirms its commitment to deliver greater transparency and insight into the ratings process and simplify access for all market participants. Ratings are organized alphabetically by industry sector. The scores reflect the building blocks of the corporate ratings framework (see chart 1). Modifiers and components related to our group rating methodology or government-related entity methodology are indicated only where they have a positive or negative effect on the rating. The report reflects corporate credit ratings and scores as of Oct. 31, 2020. This document will not be updated for future rating actions or score revisions. To keep it concise, the list only discloses scores for the main rated entity of larger corporate groups. We omit certain entities such as subsidiaries or holding companies where the ratings are linked to those on their parent companies.
    [Show full text]
  • Annual Report of the PHOENIX Group for 2016/2017
    CARING FOR PEOPLE ANNUAL REPORT 2016/17 PHOENIX GROUP IN FIGURES Key figures of the PHOENIX group 2012/13 2013/14 5) 2014/15 2015/16 6) 2016/17 Revenue in €k 21,218,687 21,791,268 22,567,998 23,247,428 24,436,695 Total operating performance 1) in €k 25,251,336 25,916,290 27,278,243 28,484,595 30,232,784 Total income 2) in €k 2,319,147 2,217,379 2,277,295 2,416,548 2,567,225 Profit before tax in €k 230,723 3) 143,092 361,278 318,985 242,514 Profit before tax, before non-recurring items 4) in €k 329,156 253,094 296,558 335,321 289,792 Equity in €k 2,103,800 2,161,841 2,481,491 2,726,468 2,849,764 Equity ratio in % 28.7 29.4 32.1 35.1 33.1 Net debt in €k 1,611,518 1,330,855 1,068,749 1,121,561 1,377,547 Company rating (Standard & Poor’s) BB BB BB BB+ BB+ Employees (total) 28,698 28,555 28,922 29,745 34,145 Employees (full-time) 23,932 23,850 24,153 24,842 26,611 1) Total operating performance = revenue + handled volume (handling for service charge). 2) Total income = gross income + other operating income (previous years 2010/11 up to 2012/13 adjusted due to changes in reporting). 3) Adjusted due to the application of IAS 19R. 4) Adjusted for impairment losses on goodwill, effects resulting from the sale of financial assets, one-off effects related to refinancing measures in 2012, expenditures associated with the PHOENIX FORWARD optimisation programme, changes in pension schemes 2014/15 and 2015/16, Mediq acquisition costs, and tax audits for previous years.
    [Show full text]
  • Annual Report for the Year 2019/20 PHOENIX PIB Dutch Finance B.V
    PHOENIX PIB Dutch Finance B.V. Annual Report for the year 2019/20 PHOENIX PIB Dutch Finance B.V. Contents Directors’ report 1 Financial statement 2019/20 7 Balance sheet as at 31 January 2020 8 Statement of income for the year 2019/20 9 Cash flow statement for the year 2019/20 10 Notes to the 2019/20 financial statements 11 Other information 27 i PHOENIX PIB Dutch Finance B.V. Directors’ report The Board of Directors of PHOENIX PIB Dutch Finance B.V. (the “Company”) is pleased to present you its financial statements for the financial year ended 31 January 2020. All amounts in the directors’ report are stated in EUR 1,000, unless indicated otherwise. General information on the legal entity PHOENIX PIB Dutch Finance B.V., with its statutory seat and its office in Maarssen, the Netherlands, serves as a financing company for the affiliated company PHOENIX PIB Finance B.V. (registered with the trade register of the Chamber of Commerce under number 57769435) and was founded on 17 April 2013. PHOENIX PIB Dutch Finance B.V. is a fully-owned subsidiary of PHOENIX PIB Dutch Holding B.V., Maarssen, the Netherlands and is ultimately owned by PHOENIX Pharma SE, Mannheim, Germany (“PHOENIX”). The Company is part of a fiscal unity for corporate income tax purposes together with the principal of the fiscal unity, PHOENIX PIB Dutch Holding B.V. and PHOENIX PIB Finance B.V., a fully-owned subsidiary of PHOENIX PIB Dutch Holding B.V. The Company recognizes its current tax result in the financial statements.
    [Show full text]
  • 2. Impacts of Foreign Takeovers in the Nordic Countries - What Do the Company Case Studies Tell Us?
    Foreign Takeovers in the Nordic Countries 2. Impacts of foreign takeovers in the Nordic countries - what do the company case studies tell us? A report produced by NIFU STEP, ITPS, VTT, DTU and RANNIS Published by NIFU STEP, Oslo, January 2005 Financed by Impacts of Foreign Takeovers in the Nordic Countries - what do the company case studies tell us? Juha Oksanen & Nina Rilla (eds.), VTT Technology Studies ii Published by NIFU STEP Studies in Innovation, Research and Education Hammersborg torg 3 0179 Oslo January 2005 www.nifustep.no © NIFU STEP and its FOTON partners 2005 Cover photo © Photos.com The main objectives of FOTON are to study how foreign takeovers of firms in the Nordic countries affect local innovation capabilities and how this issue is approached by policy makers. FOTON is made up of three modules: The first module is a statistical exercise providing an overall picture of foreign industrial ownership in the Nordic countries. A quantitative analysis of the effects of foreign ownership on firms’ innovation performance is presented in FOTON report No. 3: Corporate Innovation Activities - Does Ownership Matter? Report No. 1 has a short overview of available statistics. The second module consists of case studies of Nordic firms that have been taken over by foreign companies. To allow for inter-Nordic comparisons, takeovers within two specific industries have been selected: Pharmaceuticals and ICT. The main focus of the case studies is on how the takeovers have affected innovation capabilities, not only in the acquired firms but also – through these firms’ linkages to local actors – in the surrounding innovation systems.
    [Show full text]
  • Sustainability Brochure
    Sustainability CONCISE 2017/18 PHOENIX. WHO WE ARE. The PHOENIX group is a leading European health service provider. It was formed in 1994 from the merger of five regional pharmaceutical whole salers in Germany. Today, the company employs around 36,000 employees and offers a unique coverage in Europe. WE’RE TALKING STRAIGHT. Pharmaceutical products, logistics, transport, retail, services – and people: Our business is complex. Indispensable for health and quality of life, with good opportunities for profitable growth. At the same time, however, it also carries risks and has an impact on the world around us. We move many vehicles, consume energy and resources, have to comply with a wide variety of regulations, work with sensitive data and are Pharma Services provides services along the responsible for around 36,000 employees. entire pharmaceutical supply In pharmaceutical wholesale chain. The All-in-One concept We are aware of that and this is the key to improving every day. Our motto the PHOENIX group has stands for a comprehensive 164 distribution centres range of services that benefits is to speak plainly: Where do we stand? What course can and must we in 27 European countries drug manufacturers, set? We ensure our key figures and performance are transparent and set from which it supplies drugs pharmacies, and patients. ourselves ambitious goals that we consistently pursue across all divisions. and other health products In pharmacy retail to pharmacies and the PHOENIX group operates medical institutions. around 2,500 of its own After all, sustainability has long been inextricably linked to our identity pharmacies in 14 countries and our growth.
    [Show full text]